JP2022500485A5 - - Google Patents

Info

Publication number
JP2022500485A5
JP2022500485A5 JP2021517311A JP2021517311A JP2022500485A5 JP 2022500485 A5 JP2022500485 A5 JP 2022500485A5 JP 2021517311 A JP2021517311 A JP 2021517311A JP 2021517311 A JP2021517311 A JP 2021517311A JP 2022500485 A5 JP2022500485 A5 JP 2022500485A5
Authority
JP
Japan
Prior art keywords
approximately
hours
dosage form
unit dosage
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053413 external-priority patent/WO2020069288A1/en
Publication of JP2022500485A publication Critical patent/JP2022500485A/ja
Publication of JP2022500485A5 publication Critical patent/JP2022500485A5/ja
Pending legal-status Critical Current

Links

JP2021517311A 2018-09-27 2019-09-27 グラピプラント単位剤形 Pending JP2022500485A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737285P 2018-09-27 2018-09-27
US62/737,285 2018-09-27
US201962834513P 2019-04-16 2019-04-16
US62/834,513 2019-04-16
PCT/US2019/053413 WO2020069288A1 (en) 2018-09-27 2019-09-27 Grapiprant unit dosage forms

Publications (2)

Publication Number Publication Date
JP2022500485A JP2022500485A (ja) 2022-01-04
JP2022500485A5 true JP2022500485A5 (cg-RX-API-DMAC7.html) 2022-10-05

Family

ID=69953354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517311A Pending JP2022500485A (ja) 2018-09-27 2019-09-27 グラピプラント単位剤形

Country Status (6)

Country Link
US (1) US20210353648A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856177A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022500485A (cg-RX-API-DMAC7.html)
CN (1) CN113260363A (cg-RX-API-DMAC7.html)
CA (1) CA3113468A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020069288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia
CN115919756B (zh) * 2022-10-19 2024-08-23 梅州市珍宝金柚实业有限公司 一种金柚原浆口服液及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011792D1 (de) * 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
JP2014520865A (ja) * 2011-07-15 2014-08-25 ユーファーマ プロプライエタリー リミテッド 制酸剤、麻酔薬、ならびに二酸化ケイ素と二酸化チタンとを含んでなる無機マトリックスを含んでなる経口用組成物
CA2918277C (en) * 2013-07-16 2021-02-16 Cadila Pharmaceuticals Limited Indole-3-carbinol derivatives
TWI664969B (zh) * 2014-03-06 2019-07-11 雅瑞塔那醫療公司 格拉匹綸(grapiprant)組合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2018510178A5 (cg-RX-API-DMAC7.html)
CA2568443A1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
JP2023552700A5 (cg-RX-API-DMAC7.html)
JP2010065060A (ja) 心不全処置のための複合治療
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
CN110123771A (zh) 药物组合药物
JP2005528429A (ja) 活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と1日あたりの投薬量
JP2023139157A (ja) 抗線維化療法を投与する方法
AU2023397768A1 (en) Stat3 inhibitors for use in the treatment of non-viral liver cancer
BRPI0717052A2 (pt) Tratamento de doença reumatoide com glucocorticoide de liberação retardada
JP2004091473A (ja) 色素沈着改善治療薬
JP2022177119A5 (cg-RX-API-DMAC7.html)
WO2012071535A2 (en) Pediatric formulation
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
AU2011339150A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
CN112912070A (zh) 夜间多尿的治疗或预防剂
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
JP6420923B1 (ja) 医薬
CN115315258A (zh) 肾功能保护剂
TWI744858B (zh) 治療精神疾病之控釋藥物組合物和方法